Your shopping cart is empty
Subscriber login
REGISTER FOR FREE EZINES
Advanced Search
- Please Select -
Regulation
Business Development
Drug Manufacturing
Device Manufacturing
Quality Management
Home
Books
Conferences
DVDs
Newsletters
Form 483
s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us
Check out our free and informative ezines and sign up now
Sign Up
Home
>
Newsletters
>
FDAnews Drug Daily Bulletin
> Astex Pharma Ends Development of Lung Cancer Drug
FDAnews Drug Daily Bulletin
Sept. 25, 2012
| Vol. 9 No. 188
Astex Pharma Ends Development of Lung Cancer Drug
Cancer drugmaker Astex Pharmaceuticals said it would discontinue the development of its experimental small-cell lung cancer drug, Amuvatinib, as the drug failed to achieve a high enough response rate in patients in a mid-stage study.
Reuters
Register Now
Print This Page
Email This Article
RSS
Archives
Related Articles
Mylan Launches Generic Tricor Tablets
Is the FDA Approving too Many Drugs Starting with X and Z?
Court Rejects Merck Deal Over Vioxx
Citizens in Poor EU States Can’t Afford Medicines, Health Promoters Say